TheranosticTrials.org

Clinical Trial · NCT05065736

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Overview

The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.

Sponsor

Case Comprehensive Cancer Center

Phase

Early Phase 1

Contacts

Roberto Vargas, MD (CONTACT)

taussigresearch@ccf.org

866-223 8100

Roberto Vargas, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05065736

Drug / Compound

Clofarabine

Isotope(s):
Target(s):
  • dCK
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Subjects must have measurable disease per RECIST 1.1
  • * Histologically or cytologically proven metastatic cancer (including carcinoma, adenocarcinoma, sarcoma, or neuroendocrine cancer).
  • ECOG performance status 0-1
  • Over 18 years of age
  • Subjects must have metastatic disease, confirmed by imaging, typically a CT scan of the chest/abdomen/pelvis.

Exclusion

  • * Within 6 months prior to enrollment on this study: myocardial infarction, severe/unstable angina, severe peripheral vascular disease (claudication) or procedure on peripheral vasculature, coronary/peripheral artery bypass graft, New York Heart Association grade II or greater congestive heart failure, cerebrovascular accident or transient ischemic attack, clinically significant bleeding or pulmonary embolism.
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
  • Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study because study drugs have the potential for teratogenic or abortifacient effects.